News about ARI0002h

Hospital Clínic-IDIBAPS, pioneer in CAR T-cell therapies for cancer with over 500 patients treated

Hospital Clínic-IDIBAPS is the only hospital in Europe to have fully developed two academic CAR T-cell therapies that have been approved by a regulat1

Research June 11 2024 2025-02-10

Biomarkers of response to CAR T-cell therapy with ARI-0002h in refractory multiple myeloma are described

A study published recently in the journal Clinical Cancer Research identified biomarkers that can predict the response to CAR T-cell therapy targetin1

Research February 16 2024 2025-02-10

Presentation of the first model to predict response to CAR T-cell therapy in multiple myeloma

An international team, co-led by the Hospital Clínic-IDIBAPS, has identified four biomarkers that determine the risk of the recurrence of this cancer1

Research July 4 2023 2025-02-10

The CAR T-cell therapy from the Hospital Clínic-IDIBAPS for multiple myeloma is effective in patients with refractory disease

A multicentre study led by the Hospital Clínic Barcelona-IDIBAPS demonstrates the efficacy of the CAR T-cell therapy ARI0002h in treating patients wi1

News about ARI0002h

Hospital Clínic-IDIBAPS, pioneer in CAR T-cell therapies for cancer with over 500 patients treated

Biomarkers of response to CAR T-cell therapy with ARI-0002h in refractory multiple myeloma are described

Presentation of the first model to predict response to CAR T-cell therapy in multiple myeloma

The CAR T-cell therapy from the Hospital Clínic-IDIBAPS for multiple myeloma is effective in patients with refractory disease

Subscribe to the Newsletter of Clínic